Precipio Beheer

Beheer criteriumcontroles 4/4

De CEO Precipio is Ilan Danieli, benoemd in Jun2017, heeft een ambtstermijn van 7.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 473.44K, bestaande uit 63.4% salaris en 36.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.19% van de aandelen van het bedrijf, ter waarde $ 16.83K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.4 jaar en 4.9 jaar.

Belangrijke informatie

Ilan Danieli

Algemeen directeur

US$473.4k

Totale compensatie

Percentage CEO-salaris	63.4%
Dienstverband CEO	7.4yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	7.4yrs
Gemiddelde ambtstermijn bestuur	4.9yrs

Recente managementupdates

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Jun 07

Recent updates

Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price Boost

Aug 21

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Jun 07

We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

Jun 12

Precipio shares surge on HemeScreen Anemia Panel launch

Jun 08

Precipio shares surge on launching hemescreen panel for Acute Myeloid Leukemia

May 10

Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke

May 05

Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform

May 03

Analyse CEO-vergoeding

Hoe is Ilan Danieli's beloning veranderd ten opzichte van Precipio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$3m
Jun 30 2024	n/a	n/a	-US$4m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$473k	US$300k	-US$6m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$805k	US$300k	-US$12m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$2m	US$300k	-US$9m
Sep 30 2021	n/a	n/a	-US$8m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	US$452k	US$261k	-US$14m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$298k	US$250k	-US$13m
Sep 30 2019	n/a	n/a	-US$16m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$914k	US$250k	-US$20m
Sep 30 2018	n/a	n/a	-US$26m
Jun 30 2018	n/a	n/a	-US$33m
Mar 31 2018	n/a	n/a	-US$38m
Dec 31 2017	US$369k	US$250k	-US$33m

Compensatie versus markt: De totale vergoeding ($USD 473.44K ) Ilan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Ilan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ilan Danieli (52 yo)

7.4yrs

Tenure

US$473,440

Compensatie

Mr. Ilan Danieli is the Founder of Precipio, Inc. and has been its Chief Executive Officer since June 29, 2017 and serves as its President and Director. Mr. Danieli has few years managing small and medium-...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ilan Danieli	Founder	7.4yrs	US$473.44k	0.19% $ 16.8k
Ahmed Sabet	Chief Operating Officer	7.4yrs	US$265.34k	0.041% $ 3.6k
Ayman Mohamed	Chief Technology Officer	no data	US$284.50k	0.013% $ 1.1k
Matthew Gage	Chief Financial Officer	2.7yrs	geen gegevens	geen gegevens
Miri Chiko-Radomski	Chief Legal Counsel & People Officer	no data	geen gegevens	geen gegevens

7.4yrs

Gemiddelde duur

45.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PRPO is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ilan Danieli	Founder	7.4yrs	US$473.44k	0.19% $ 16.8k
Kathleen LaPorte	Independent Non Executive Director	6.3yrs	US$72.81k	0.68% $ 59.4k
Richard Sandberg	Independent Chairman of the Board	4.9yrs	US$98.43k	0.0028% $ 247.5
Ronald Andrews	Independent Director	3.7yrs	US$60.81k	0.75% $ 65.7k
Christina Valauri	Director	less than a year	geen gegevens	0.34% $ 29.6k
Douglas Fisher	Board Observer	less than a year	US$74.24k	0% $ 0
David Cohen	Independent Director	7yrs	US$59.73k	3.21% $ 280.6k
Jeffrey Cossman	Independent Director	7.2yrs	US$64.01k	0.83% $ 72.6k
Mark Rimer	Board Observer	3.7yrs	US$159.25k	geen gegevens
Mike Makrigiorgos	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gil Mor	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PRPO wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Precipio Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Precipio, Inc., Annual General Meeting, Jun 13, 2024

Precipio, Inc. Announces Board Changes

Precipio, Inc. Appoints Sharon Robins as its Senior Director of Laboratory & Hospital Sales for the Product’s Division

Precipio, Inc. Welcomes Toni-Ann Mills as its Senior Director for Learning & Development

Precipio, Inc. Appoints Keith Meadors as Senior Vice President of its Products Division

Recent updates

Third quarter 2024 earnings released: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)

Precipio Expands Bloodhound MPN Panel by Adding CALR Mutation Subtyping

Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price Boost

Second quarter 2024 earnings released: US$0.83 loss per share (vs US$1.88 loss in 2Q 2023)

New minor risk - Share price stability

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

First quarter 2024 earnings released: US$1.46 loss per share (vs US$2.61 loss in 1Q 2023)

New major risk - Financial position

Precipio, Inc., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: US$4.51 loss per share (vs US$10.73 loss in FY 2022)

Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)

Precipio, Inc. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An Opportunity

Consensus revenue estimates increase by 11%

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Market cap size

New minor risk - Share price stability

Precipio, Inc.'s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings released: US$0.54 loss per share (vs US$0.40 loss in FY 2021)

Price target decreased to US$4.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Precipio Receives Noncompliance Letter from the Nasdaq

Precipio, Inc. Appoints Sharon Robins as its Senior Director of Laboratory & Hospital Sales for the Product’s Division

Precipio, Inc. Launches New 1-Step Technology for All Hemescreen Assays

Second quarter 2022 earnings released: US$0.094 loss per share (vs US$0.14 loss in 2Q 2021)

Precipio, Inc. Welcomes Toni-Ann Mills as its Senior Director for Learning & Development

Forecast to breakeven in 2023

Precipio to distribute HemeScreen through Fisher Healthcare channel

Precipio, Inc. Appoints Keith Meadors as Senior Vice President of its Products Division

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Precipio Signs First IV-Cell Customer Agreement

Price target decreased to US$4.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Precipio, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2020)

Precipio terminates its equity line with Lincoln Park

We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

Precipio, Inc. Launches Hemescreen® Anemia Panel, One-Of-Its-Kind Testing Tool

Precipio shares surge on HemeScreen Anemia Panel launch

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.78 loss in 1Q 2020)

Precipio, Inc. Launches New Hemescreen Panel for AML, with an Unparalleled 4-Hour Turnaround-Time

Precipio shares surge on launching hemescreen panel for Acute Myeloid Leukemia

Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke

Precipio, Inc. Launches Rapid COVID-19 Antibody Test on Amazon Platform

Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform

Price target increased to US$7.00

Precipio, Inc. to Report Q4, 2020 Results on Mar 31, 2021

Precipio, Inc. Announces Board and Committee Changes

Precipio Launches COVID-19 Antibody Testing at Point-of-Care

Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups

Precipio, Inc. Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor

Precipio & ADS Biotec Launch Seven Beta Sites for IV-Cell™

Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel

Precipio, Inc.(NasdaqCM:PRPO) dropped from Russell Microcap Value Index

Precipio, Inc.(NasdaqCM:PRPO) dropped from Russell Microcap Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur